Join us for a Virtual Satellite Symposium on February 26th

• Date: February 26, 2021
• Time: 4:30pm – 5:45pm EDT

Immunosuppression (IS) minimization can decrease immediate adverse effects and unwanted long-term toxicities, but how can it be done with the utmost safety in mind?  This symposium will provide insight to challenges facing kidney and liver transplant clinicians and how biomarkers are the key to assisting with safer minimization strategies.  Also included is a preview to a novel addition of infectious disease monitoring to donor derived cell free DNA testing.

Learning Objectives:

• Identify challenging transplant patients and how to utilize biomarkers in their care
• Uncover new data from REVERSE and PRESERVE for biomarker utilization in liver transplant patients
• Review real life experience in biomarker use and IS minimization

———————— Satellite Symposium Agenda ————————

Immunosuppression minimization: How Biomarkers Can Play a Role

Topic: REVERSE and PRESERVE: Saving the Kidney in Liver Transplantation 

Speaker: Josh Levitsky, MD, MS

Professor of Medicine and Surgery Division of Gastroenterology & Hepatology Comprehensive Transplant Center at Northwestern University Feinberg School of Medicine

Topic: Immunosuppression Adequacy – Case study

Speaker: Martha Pavlakis, MD

Medical Director, Kidney and Pancreas Transplantation at Beth Israel Deaconess and Medical Center Associate Professor of Medicine at Harvard Medical School

Topic: Challenges of CNI to Belatacept Conversion

Speaker: Sarthak Virmani, MD

Transplant Nephrologist at Yale School of Medicine

To register for our Satellite Symposium, Please Click Here.

This is not an official function of the CEoT Meeting and is not endorsed by AST.